Is it true that Baricitinib can stop hair loss suddenly? Or does it take time?

Baricitinib has drawn interest in recent years as a treatment for severe alopecia areata. A common question is whether it stops hair loss immediately or takes time to show results. This article looks at the clinical trials and the FDA approval.

The promise of Baricitinib: what is it and how does it act on hair?

Baricitinib is a drug originally developed to treat rheumatoid arthritis, and more recently approved to treat severe alopecia areata. It belongs to a class of drugs known as JAK inhibitors, or Janus kinase inhibitors. This enzyme plays a key role in communication between the body's immune cells. When this signaling is disrupted, as in autoimmune diseases, the immune system can attack the body’s own tissues, such as hair follicles. In alopecia areata, the immune system mistakenly targets the follicles as threats and attacks them, disrupting their normal function and halting hair growth. By blocking the JAK-STAT pathways (involved in that inflammatory response), Baricitinib disrupts the faulty communication between immune cells and allows hair follicles to reenter the growth phase.

However, this process is not instantaneous. Hair regeneration requires reactivation of the natural hair cycle, in which follicles must transition from the resting (telogen) phase to the active growth (anagen) phase. This takes time, and while Baricitinib may promote that transition, it does not produce an immediate effect.

To understand precisely how and when Baricitinib works, it's essential to examine the evidence from clinical trials.

A key study is that by King et al. (2022), published in the New England Journal of Medicine, which included two phase 3 clinical trials called BRAVE-AA1 and BRAVE-AA2. A total of 1,200 adult patients with severe alopecia areata, defined as hair loss exceeding 50% of the scalp, participated in the study.Participants were randomly assigned to receive 2 mg, 4 mg of Baricitinib, or a placebo daily for 36 weeks. Progress was assessed using the SALT (Severity of Alopecia Tool) scale, a standardized method for measuring hair loss extent. At week 36, 38.8% (BRAVE-AA1) and 35.9% (BRAVE-AA2) of patients on 4 mg reached a SALT score of 20 or less (80% or more scalp coverage), compared with 6.2% and 3.3% on placebo; the 2 mg dose reached 22.8% and 19.4%. These benefits did not appear immediately. In the trials, improvement built gradually over the 36 weeks, and results at week 36 were better than at earlier visits. This does not support the idea that baricitinib suddenly stops hair loss.

Although baricitinib is approved for severe alopecia areata, it has not been shown to work to other types of hair loss, such as androgenetic alopecia (the most common form of baldness, especially in men) or telogen effluvium, which can be linked to stress, hormonal imbalances, or medication use.

There are no controlled trials of baricitinib for androgenetic alopecia, and it is not approved for it. This is important because many patients with different types of hair loss may have unrealistic expectations about the drug’s benefits in their particular case. One of the factors that most influences the belief that Baricitinib acts suddenly is the patient’s subjective experience. Some people report noticing a decrease in daily hair shedding within a few weeks of starting treatment. This may be interpreted as an immediate effect, when in fact it could be due to multiple factors such as natural hair cycle variations, the placebo effect, or a temporary pause in the progression of the condition. It’s crucial to differentiate between a reduction in hair shedding and visible hair regrowth. In the clinical trials, scalp coverage improved gradually over months rather than weeks. Moreover, the size of the effect may depend on individual factors such as the previous duration of alopecia, the severity of hair loss, age, and the patient’s immune response. In other words, not everyone responds the same way or at the same speed.

Are we talking about a definitive cure?

A common question among patients is whether Baricitinib represents a cure for alopecia areata. The short answer is no. Its effect depends on continued use. In the BRAVE-AA1 withdrawal study, 80% of the 40 responders switched to placebo had lost their regrowth by week 152, compared with 7% who stayed on baricitinib (King et al., JAMA Dermatology 2024). This means that Baricitinib does not offer a permanent or definitive solution. It works as a disease management tool that, once discontinued, allows the immune system to resume attacking the follicles. Baricitinib carries an FDA boxed warning for serious infections including tuberculosis, death from any cause, cancer, major cardiovascular events and blood clots. Doctors screen for TB before starting and monitor blood counts, liver enzymes and cholesterol. The label also says to avoid live vaccines and warns the drug may harm an unborn baby.

User Experiences

Community feedback about Baricitinib's effect on hair loss, particularly its onset of action, reveals a mixed and nuanced understanding. While clinical trials suggest Baricitinib can lead to significant hair regrowth in patients with alopecia areata over several months, community discussions on Tressless show that users generally do not see “sudden” results. Instead, the treatment is associated with a gradual response over time.

In one notable thread, a user asked if anyone had experience with Baricitinib (Olumiant) and why it isn't more widely discussed despite being approved for alopecia areata. The replies in this thread indicated a general lack of personal experiences with the drug. Some users noted that its high cost and limited use cases — being mostly approved for autoimmune-related hair loss like alopecia areata and not androgenic alopecia — contribute to its low visibility in the community. Another user shared that they had ordered Baricitinib but had not yet begun treatment. Others in that thread expressed curiosity rather than direct experience, with some speculating about its potential and others cautioning about its immunosuppressive nature. One post explored the idea of a topical version of Baricitinib for androgenic alopecia, though responses clarified that it is currently only approved for autoimmune hair loss and not for typical male pattern baldness.

A different thread by a dermatologist with an interest in alopecia provided more clarity. The expert discussed Baricitinib among other treatments, explaining that it’s mainly effective in alopecia areata, with results typically seen after several months of consistent use. They emphasized that Baricitinib doesn’t work for androgenic alopecia and that even in suitable patients, it does not act instantly — improvements can take three to six months or longer.

Taken together, Tressless users report that Baricitinib is a treatment requiring patience. Users describe results mainly in alopecia areata and say expectations of sudden hair regrowth are unrealistic. Most feedback matches the trials, which showed gradual regrowth over months under medical supervision.

Conclusion: Does Baricitinib stop hair loss suddenly?

Baricitinib does not act suddenly to stop hair loss. In the trials, regrowth built gradually, and about a third of adults with severe alopecia areata on 4 mg reached 80% or more scalp coverage by week 36. It is approved only for severe alopecia areata in adults, it carries an FDA boxed warning, and regrowth is usually lost after stopping.

References

King B, Ohyama M, Kwon O, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022;386(18):1687-1699. https://pubmed.ncbi.nlm.nih.gov/35334197/

King B, Ko J, Kwon O, et al. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. JAMA Dermatol. 2024;160(10):1075-1081. https://pubmed.ncbi.nlm.nih.gov/39141364/

U.S. National Library of Medicine. OLUMIANT (baricitinib) tablets, prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf

U.S. Food and Drug Administration. (2022). FDA approves first systemic treatment for alopecia areata. https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata

Reddit user. (2021, April 26). Lilly to seek first approval of an autoimmune drug for hair loss. Reddit. https://reddit.com/r/tressless/comments/mzafgd/lilly_to_seek_first_approval_of_an_autoimmune/

Reddit user. (2022, Dec 6). Olumiant active ingredient Baricitinib. Reddit. https://reddit.com/r/tressless/comments/zdr1tf/olumiant_active_ingredient_baricitinib/

Reddit user. (2023, Jun 28). Anyone heard of or have experience using baricitinib? Reddit. https://reddit.com/r/tressless/comments/14kv4wk/anyone_heard_of_or_have_experience_using/

Reddit user. (2023, Feb 9). What are the odds baricitinib will get a topical otc version for androgenic alopecia? Reddit. https://reddit.com/r/tressless/comments/10y9lxi/what_are_the_odds_baricitinib_will_get_a_topical/

Reddit user. (2022, Sep 3). I am a dermatologist with a clinical interest in alopecia. AMA. Reddit. https://reddit.com/r/tressless/comments/x4jltq/i_am_a_dermatologist_with_a_clinical_interest_in/